Literature DB >> 10192882

Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS.

R Bartl1, B Frisch.   

Abstract

Multiple myeloma (MM) is characterized by plasma cell infiltration in the bone marrow, suppression of normal haematopoiesis, destruction of bone, renal failure and recurrent infections. The extent of organ involvement, severity of complications, drug sensitivity and therefore the clinical course differ widely among patients. Specific and reliable laboratory examinations and especially morphology including both biopsy and aspirations are required to evaluate its aggressivity and extent. In this review of MM and its variants we emphasize the impact of morphology on the diagnostic and prognostic approach to MM and MGUS, and on the planning and monitoring of appropriate therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10192882

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

1.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors:  Scott A Ely; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

2.  Pancytopenia in Multiple Myeloma- An Enigma: Our Experience from Tertiary Care Hospital.

Authors:  Hanaganahalli B Sridevi; Sharada Rai; Pooja K Suresh; Meludurgamutt S Somesh; Jessica Minal
Journal:  J Clin Diagn Res       Date:  2015-11-01

3.  Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.

Authors:  Svitlana Demyanets; Alexandra Kaider; Ingrid Simonitsch-Klupp; Günther Bayer; Almira Subasic; Renate Thalhammer; Harald Esterbauer; Maria T Krauth; Hermine Agis; Thomas Reiter; Ilse Schwarzinger
Journal:  Ann Hematol       Date:  2020-09-15       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.